July 17, 2024 --- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has accepted for review the supplemental new drug application (sNDA) for toripalimab (trade name: TUOYI®, product code: JS001) combined with bevacizumab for the first-line treatment of unresect

May 20, 2024 -- PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in equity financing from institutional investors and current shareholders. In addition, the Company closed on a new senior secured credit facility with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”), part of Avenue Capital Group. The credit agreement provides up to $10 million in total term loan capital

As we begin the new year, there is a lot of talk in the drug development world about Federal Drug Administration (FDA) guidance documents for clinical and decentralized clinical trials (DCTs). This chatter is understandable because we’re likely to see some emphasis put into previous documents that have not been rigidly enforced. Unfortunately, a lot of trial sponsors aren’t thinking about these guidance documents in a holistic manner; rather, they are treating them in silos. And that’s a mistake

Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE® CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients l

SHANGHAI, Oct 13 (Reuters) - China's daily count of new coronavirus cases has doubled since September, hardening the resolve of authorities to eliminate outbreaks as quickly as they appear and dimming hopes for an easing in their zero-COVID stance. China reported 1,624 new COVID-19 infections for Oct. 12, of which 372 were symptomatic and 1,252 asymptomatic, the National Health Commission said on Thursday. That compares with 1,890 new cases a day earlier – 417 symptomatic and 1,473 asymptomatic

VANCOUVER, British Columbia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (OTC: AGFAF), a growth-oriented and diversified company focused on the international cannabis industry, applauds President Joseph Biden’s recent statement (the “Statement”) regarding cannabis reform at the Federal level of the United States (the “US”). On Thursday, October 6, 2022, President Biden announced that previous Federal cannabis convictions could be completely pardon

REDWOOD CITY, Calif., Oct. 10, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that on October 1, 2022, UnitedHealthcare ("United") released an update to its medical coverage policy (number 2022T0567V) and added language to indicate spinal cord stimulation (SCS) devices are not covered for treating chronic intractable back pain without prior spine surgery (N

SAN DIEGO and TORONTO, Oct. 7, 2022 /PRNewswire/ - StateHouse Holdings Inc. ("StateHouse" or the "Company") (CSE: STHZ) (OTCQX: STHZF), a California-focused, vertically integrated cannabis enterprise, today applauded President Joe Biden for announcing substantial reforms to cannabis enforcement in the United States. On Thursday, the President announced a proposed blanket pardon for people convicted of federal marijuana possession offences, and asked state governors to do the same. In addition, h